{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-028914","form_type":"8-K","ticker":"SEER","cik":"0001726445","company_name":"Seer, Inc.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.899696+00:00","generated_at":"2026-06-22T04:07:16.196871+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Seer Q3 revenue $4.0M, net loss $24.0M; FY2022 guidance reaffirmed","bullets":["Revenue of $4.0M, up 82% YoY from $2.2M, driven by Proteograph product suite sales.","Net loss of $24.0M vs $18.4M in Q3 2021; operating expenses $27.0M including $9.1M stock-based comp.","Gross margin 49%; cash, cash equivalents and investments $441.0M at Sep 30, 2022.","Full-year 2022 revenue guidance reaffirmed at $14.0M to $16.0M.","Published results in Advanced Materials; customer adoption increasing with multiple studies underway."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-028914","json":"https://secwatch.observer/filing/0001628280-22-028914.json","markdown":"https://secwatch.observer/filing/0001628280-22-028914.md","text":"https://secwatch.observer/filing/0001628280-22-028914.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1726445/000162828022028914/0001628280-22-028914-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1726445/000162828022028914/seer-20221108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T04:07:16.196871+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bcaaf1c79df78409bff5adf9ab531564bccc2f24","claim":"Seer, Inc. reported the third quarter ended September 30, 2022 results: revenue $4.0 million, net income $24.0 million.","evidence_excerpt":"Revenue was $4.0 million for the three months ended September 30, 2022, as compared to $2.2 million for the three months ended September 30, 2021. The increase was primarily due to increased sales of the Proteograph Product Suite and its related products. Product-related revenue for the third quarter of 2022 was $3.9 million, including $1.3 million of related party revenue, and consisted of sales of SP100 instruments, consumable kits and platform evaluations. Gross profit was $1.9 million and gross margin was 49% for the third quarter of 2022. Operating expenses were $27.0 million for the third quarter of 2022, including $9.1 million of stock-based compensation, as compared to $19.6 million, including $6.8 million of stock-based compensation, for the corresponding prior year period. The increase in expenses was driven by increased employee compensation and other related expenses, including stock-based compensation, and increased expenses related to the expansion of the company’s facili","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1726445/000162828022028914/0001628280-22-028914-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Revenue","value":"$4.0 million"},{"label":"Net income","value":"$24.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"eb19e7391ac599e07ed1f91c5cc8aa493ed17aaa","claim":"Seer, Inc. updated its full year 2022 guidance (reaffirmed).","evidence_excerpt":"Seer continues to expect full year 2022 revenue to be in the range of $14.0 million to $16.0 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1726445/000162828022028914/0001628280-22-028914-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2022"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}